Abbott Laboratories Rates High in Multi-Factor Model Analysis

Abbott Laboratories (ABT) achieves a notable 75% rating in a recent report based on the Multi-Factor Investor model. The stock demonstrates strong fundamentals yet has mixed results across specific investment criteria, indicating potential risks and opportunities for investors.

Date: 08-11-2024

AI Rating: 5

Abbott Laboratories (ABT) has been analyzed under the Multi-Factor Investor model founded by Pim van Vliet. The report highlights that ABT rates with a score of 75%, which suggests a favorable view based on its fundamentals and valuation. However, it is important to note that a score under 80% indicates a lack of strong interest. Given the market cap is labeled as 'PASS', it suggests that the company is considered stable in terms of its size and can attract significant investment.

Additionally, the criteria of standard deviation passed, indicating that the stock may be less volatile compared to others in its sector. However, the twelfth minus one momentum, a measure of price momentum, is described as 'NEUTRAL', which could signify that the stock is not showing a significant upward or downward trend recently.

Furthermore, the net payout yield was also marked as 'NEUTRAL', indicating uncertainty in returns to shareholders compared to the market's expectations. The final rank is listed as 'FAIL', which poses a concern, suggesting that despite meeting some requirements, overall, it does not satisfy all criteria for an attractive investment opportunity.

While not specifically discussed in this report, factors like Earnings Per Share (EPS), Revenue Growth, Net Income, Profit Margins, Free Cash Flow, and Return on Equity were not mentioned. This lack of data might suggest caution for investors looking for detailed financial metrics to gauge the company's performance further.

Stocks: ABT